TABLE 4.
Association between PD-1 expression on ICs and clinicopathological factors.
| Clinicopathological characteristics | MEC (n = 26) | ACC (n = 27) | TBP (n = 13) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PD-1 IC <1% | PD-1 IC ≥ 1% | p-value a | PD-1 IC <1% | PD-1 IC ≥ 1% | p-value a | PD-1 IC <1% | PD-1 IC ≥ 1% | p-value a | ||
| Age (years) | ≤55 | 17 | 3 | 0.558 b | 11 | 1 | 0.999 b | 6 | 1 | 0.999 b |
| >55 | 4 | 2 | 12 | 3 | 5 | 1 | ||||
| Gender | Male | 13 | 3 | 0.999 b | 7 | 2 | 0.582 b | 9 | 2 | 0.999 b |
| Female | 8 | 2 | 16 | 2 | 2 | 0 | ||||
| Smoking history | Never smoker | 11 | 3 | 0.613 b | 9 | 2 | 0.582 b | 3 | 0 | 0.218 b |
| Ex-smoker | 1 | 0 | 5 | 1 | 1 | 0 | ||||
| Smoker | 4 | 2 | 4 | 1 | 4 | 0 | ||||
| nd | 5 | 0 | 5 | 0 | 3 | 2 | ||||
a
p values refer to PD-1 negative versus PD-1 positive subgroups.
b
Fisher’s exact test was used between categorical variables; MEC, mucoepidermoid carcinoma; ACC, adenoid cystic carcinoma; TBP, tracheobronchial papilloma; IC, immune cell; nd, no data; PD-1, programmed death-1.